Patient Characteristics and Results of Virus Surveillance
| UPN . | Age/Sex . | Disease . | BTF . | TTV . | Donor TTV . | HBV . | HCV . | HGV . |
|---|---|---|---|---|---|---|---|---|
| 1 | 20/M | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (−) |
| 4 | 24/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 6 | 47/F | CML | (−)/(+) | (+) | (−) | (−) | (−) | (−) |
| 7 | 24/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 9 | 36/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 10 | 35/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
| 12 | 23/M | SAA | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 15 | 41/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
| 17 | 27/M | MDS | (+)/(+) | (+) | (+) | (−) | (−) | (+) |
| 19 | 27/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 20 | 20/M | CML | (−)/(+) | (+) | (−) | (−) | (−) | (−) |
| 21 | 35/M | CML | (−)/(+) | (+) | (+) | (−) | (−) | (−) |
| 22 | 18/F | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (−) |
| 26 | 18/M | ALL | (+)/(+) | (+) | NT | (−) | (−) | (−) |
| 27 | 26/M | ALL | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 28 | 25/M | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (+) |
| 29 | 40/F | MDS | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 31 | 48/M | MDS | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 32 | 28/M | CML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 33 | 46/F | ALL | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 34 | 45/F | CML | (−)/(+) | (−) | NT | (−) | (−) | (−) |
| 35 | 47/M | CML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 36 | 37/M | AML | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 38 | 39/M | AML | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 39 | 35/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
| UPN . | Age/Sex . | Disease . | BTF . | TTV . | Donor TTV . | HBV . | HCV . | HGV . |
|---|---|---|---|---|---|---|---|---|
| 1 | 20/M | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (−) |
| 4 | 24/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 6 | 47/F | CML | (−)/(+) | (+) | (−) | (−) | (−) | (−) |
| 7 | 24/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 9 | 36/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 10 | 35/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
| 12 | 23/M | SAA | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 15 | 41/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
| 17 | 27/M | MDS | (+)/(+) | (+) | (+) | (−) | (−) | (+) |
| 19 | 27/M | AML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 20 | 20/M | CML | (−)/(+) | (+) | (−) | (−) | (−) | (−) |
| 21 | 35/M | CML | (−)/(+) | (+) | (+) | (−) | (−) | (−) |
| 22 | 18/F | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (−) |
| 26 | 18/M | ALL | (+)/(+) | (+) | NT | (−) | (−) | (−) |
| 27 | 26/M | ALL | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 28 | 25/M | ALL | (+)/(+) | (−) | (−) | (−) | (−) | (+) |
| 29 | 40/F | MDS | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 31 | 48/M | MDS | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 32 | 28/M | CML | (+)/(+) | (+) | (−) | (−) | (−) | (−) |
| 33 | 46/F | ALL | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 34 | 45/F | CML | (−)/(+) | (−) | NT | (−) | (−) | (−) |
| 35 | 47/M | CML | (+)/(+) | (+) | (−) | (−) | (−) | (+) |
| 36 | 37/M | AML | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 38 | 39/M | AML | (+)/(+) | (−) | NT | (−) | (−) | (−) |
| 39 | 35/M | CML | (−)/(+) | (−) | (−) | (−) | (−) | (−) |
The histories of transfusion before and after BMT are shown at the left and right side of the oblique line in the column of BTF, respectively.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CML, chronic myelocytic leukemia; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome; BTF, blood transfusion; NT, not tested.